SCHEMBL472290

SCHEMBL472290

O=C(O)CCCN1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 1.00
CYP1A2 P05177 1/20 1.00
MAPK1 P28482 1/20 1.00
ALDH1A1 P00352 7/20 0.56
MAPT P10636 3/20 0.56
POLB P06746 1/20 0.56
HRH3 Q9Y5N1 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ALOX15 P16050 1/20 0.49
KMT2A Q03164 3/20 0.47
GFER P55789 1/20 0.46
GLA P06280 1/20 0.45
SLC22A6 Q4U2R8 1/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1858113 1.00 SMN1; SMN2 (1.00) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL9870336 0.98 CYP1A2 (0.96) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL11544283 0.98 CYP1A2 (0.96) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL1127792 0.98 CYP1A2 (0.96) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
SCHEMBL857572 0.98 SMN1; SMN2 (0.95) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
Methane SCHEMBL11633126 0.96 CYP1A2 (0.92) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
Bromide SCHEMBL11793837 0.95 SMN1; SMN2 (0.91) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL946654 0.95 SMN1; SMN2 (0.91) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
SCHEMBL2639576 0.93 CYP1A2 (0.88) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT
SCHEMBL547192 0.93 CYP1A2 (0.88) SMN1; SMN2CYP1A2MAPK1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384969-A Transfection reagent and preparation method and application thereof 上海市第六人民医院 2024-01-12 CN claimed
EP-2968145-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS Mallinckrodt LLC (US) 2016-01-20 EP claimed
CN-105188675-A Modified docetaxel liposome formulations MALLINCKRODT LLC 2015-12-23 CN claimed
WO-2014160392-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS MALLINCKRODT LLC (US) 2014-10-02 WO claimed
US-8598359-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2013-12-03 US claimed
US-20100113450-A1 Agent for Preventing and Alleviating Wrinkles SHISEIDO COMPANY LTD. (JP) 2010-05-06 US claimed
EP-2136859-A2 NITRIC OXIDE DONATING MEDICAL DEVICES AND METHODS OF MAKING SAME Medtronic Vascular Inc. (US) 2009-12-30 EP claimed
EP-2123253-A1 WRINKLING-PREVENTING AND -MODIFYING AGENT Shiseido Company, Ltd. (JP) 2009-11-25 EP claimed
WO-2008112391-A2 NITRIC OXIDE DONATING MEDICAL DEVICES AND METHODS OF MAKING SAME MEDTRONIC VASCULAR INC. (US) 2008-09-18 WO claimed
US-20080220040-A1 Nitric Oxide Donating Medical Devices and Methods of Making Same MEDTRONIC VASCULAR, INC. (US) 2008-09-11 US claimed
EP-0882712-B1 PROCESS FOR PREPARING ACID SALTS OF GAMMA-(PIPERIDYL)BUTYRIC ACID KOEI CHEMICAL CO (JP) 2003-04-23 EP claimed
US-6197961-B1 HYDROGENATION OF G-(PYRIDYL)BUTYRIC ACID SALT IN SOLVENT USING PALLADIUM, RHODIUM, OR RUTHENIUM CATALYST; HYDROLYSIS, DECARBOXYLATION KOEI CHEMICAL CO., LTD. (JP) 2001-03-06 US claimed
EP-0882712-A1 PROCESS FOR PREPARING ACID SALTS OF $g(g)-(PIPERIDYL)BUTYRIC ACID KOEI CHEMICAL CO., LTD. (JP) 1998-12-09 EP claimed
US-12551418-B2 Cosmetic containing ultraviolet wavelength converting substance and medicinal agent SHISEIDO COMPANY, LTD. (JP) 2026-02-17 US disclosed
US-20250154140-A1 ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF Sunnybrook Research Institute (CA) 2025-05-15 US disclosed
US-20250082559-A1 EXTERNAL-USE SKIN PREPARATION COMPOSITION SHISEIDO COMPANY, LTD. (JP) 2025-03-13 US disclosed
US-4025630-A Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication ABBOTT LABORATORIES (US) 1977-05-24 US disclosed
US-4020163-A Use of heterocyclic esters of 5H-[1]benzopyrano [3,4-b]pyridines as analgesics SHARPS ASSOCIATES (US) 1977-04-26 US disclosed
US-3991194-A Heterocyclic esters of benzopyranopyridines SHARPS ASSOCIATES (US) 1976-11-09 US disclosed
US-3941782-A Heterocyclic esters of benzopyrans SHARPS ASSOCIATES (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082559-A1 EXTERNAL-USE SKIN PREPARATION COMPOSITION TYR, CUTA, NACA SMN1; SMN2 4414/4885CYP1A2 302/4885MAPK1 2544/4885
US-20100113450-A1 Agent for Preventing and Alleviating Wrinkles GABRB1, GABRB2, GABBR1 SMN1; SMN2 1147/4885CYP1A2 706/4885MAPK1 2400/4885
US-20250154140-A1 ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF BAK1, BAX, BCL2 SMN1; SMN2 424/4885CYP1A2 2086/4885MAPK1 1062/4885
US-12551418-B2 Cosmetic containing ultraviolet wavelength converting substance and medicinal agent GLA, PGA5, AGER SMN1; SMN2 3929/4885CYP1A2 2324/4885MAPK1 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.